El colesterol HDL: ¿un nuevo objetivo terapéutico en el manejo de las dislipidemias y la ateroesclerosis? / HDL cholesterol: A new target in the treatment of lipid disorders and atherosclerosis?
Rev. méd. Chile
; 133(7): 823-832, jul. 2005. ilus, tab
Article
in Spanish
| LILACS
| ID: lil-429143
Responsible library:
BR1.1
RESUMO
Low plasma HDL cholesterol levels are an independent risk factor for atherosclerotic cardiovascular disease. During the past years, the study of HDL has been stimulated by the discovery of novel genes and proteins, which have provided new insights into the molecular and cellular mechanisms involved in HDL metabolism. In addition, recent clinical studies focused on treating low HDL as primary objective in high cardiovascular risk patients have been very encouraging. Furthermore, new drugs for raising HDL cholesterol are under development. This article reviews the recent progress in the HDL field and its important implications for the pathophysiology and treatment of atherosclerosis. In the near future, we expect that new drugs with specific and beneficial effects on HDL metabolism and the associated cardiovascular risk should improve the current approach to this disease with high burden on health systems and society.
Full text:
Available
Collection:
International databases
Health context:
SDG3 - Health and Well-Being
Health problem:
Target 3.4: Reduce premature mortality due to noncommunicable diseases
Database:
LILACS
Main subject:
Atherosclerosis
/
Dyslipidemias
/
Cholesterol, HDL
Type of study:
Etiology study
/
Risk factors
Limits:
Humans
Language:
Spanish
Journal:
Rev. méd. Chile
Journal subject:
Medicine
Year:
2005
Document type:
Article
/
Project document
Affiliation country:
Chile
Institution/Affiliation country:
Clínica Las Condes/CL
/
Pontificia Universidad Católica de Chile/CL